CN109843286A - 治疗瘙痒和/或搔痒的方法 - Google Patents

治疗瘙痒和/或搔痒的方法 Download PDF

Info

Publication number
CN109843286A
CN109843286A CN201780052128.4A CN201780052128A CN109843286A CN 109843286 A CN109843286 A CN 109843286A CN 201780052128 A CN201780052128 A CN 201780052128A CN 109843286 A CN109843286 A CN 109843286A
Authority
CN
China
Prior art keywords
alkyl
pharmaceutical composition
aryl
ring
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780052128.4A
Other languages
English (en)
Chinese (zh)
Inventor
M.劳顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Newrim Pharmaceutical Co Ltd
Original Assignee
Newrim Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newrim Pharmaceutical Co Ltd filed Critical Newrim Pharmaceutical Co Ltd
Publication of CN109843286A publication Critical patent/CN109843286A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780052128.4A 2016-08-23 2017-06-30 治疗瘙痒和/或搔痒的方法 Pending CN109843286A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662378435P 2016-08-23 2016-08-23
US62/378,435 2016-08-23
PCT/IB2017/053989 WO2018037295A1 (en) 2016-08-23 2017-06-30 Method for treating pruritus and/or itch

Publications (1)

Publication Number Publication Date
CN109843286A true CN109843286A (zh) 2019-06-04

Family

ID=59416750

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780052128.4A Pending CN109843286A (zh) 2016-08-23 2017-06-30 治疗瘙痒和/或搔痒的方法

Country Status (11)

Country Link
US (1) US20190175554A1 (enExample)
EP (1) EP3503884B1 (enExample)
JP (1) JP6910424B2 (enExample)
KR (1) KR20190040298A (enExample)
CN (1) CN109843286A (enExample)
AU (1) AU2017315265C1 (enExample)
CA (1) CA3033534A1 (enExample)
MX (1) MX381311B (enExample)
SG (1) SG11201901449XA (enExample)
TW (1) TW201808269A (enExample)
WO (1) WO2018037295A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115279731A (zh) * 2020-03-11 2022-11-01 诺西恩医疗公司 带电的离子通道阻滞剂及其使用方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7048051B2 (ja) * 2018-07-11 2022-04-05 正徳 染井 痒みを軽減するアトピー性皮膚炎治療剤
WO2021151059A1 (en) * 2020-01-24 2021-07-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Compounds and methods for treating or reducing pruritus
KR20240144096A (ko) 2021-11-02 2024-10-02 플레어 테라퓨틱스 인크. Pparg 역 효능제 및 그의 용도
WO2024229352A2 (en) * 2023-05-04 2024-11-07 Caamtech, Inc. Tryptamine derivatives

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521183A (en) * 1994-08-30 1996-05-28 Allergan Use of 5-HT ligands as anti-pruritic agents
EP0834317A1 (en) * 1995-06-14 1998-04-08 Institute of Immunology Co., Ltd. Ameliorant for pruritus cutaneous accompanying renal failure
CN101374833A (zh) * 2006-02-15 2009-02-25 纽瑞姆制药（1991）有限公司 新型吡喃酮-吲哚衍生物及其制备方法
US20110020436A1 (en) * 2006-09-22 2011-01-27 Guilford F Timothy Topical application of melatonin directly or in liposomes for the amelioration of itching and histamine and non-histamine related inflammatory skin changes
US20130324583A1 (en) * 2006-02-15 2013-12-05 Neurim Pharmaceuticals (1991) Ltd. Methods for treating neurological disease
CN105492430A (zh) * 2013-03-15 2016-04-13 基因泰克公司 取代的苯并噁唑及其使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028793A1 (fr) * 1996-02-07 1997-08-14 Lead Chemical Co., Ltd. Preparation a usage externe comprenant du tranilast et processus de production de cette preparation
CN1215835C (zh) * 1996-03-27 2005-08-24 东丽株式会社 酮衍生物及其在医学上的应用
JP2000327570A (ja) * 1999-05-24 2000-11-28 Nof Corp 皮膚外用剤
US6552073B1 (en) * 2002-03-01 2003-04-22 Exonhit Therapeutics Sa Compounds and methods of treating cell proliferative diseases
JP5513705B2 (ja) * 2006-03-29 2014-06-04 小林製薬株式会社 知覚過敏型肌掻痒感改善剤
KR101359078B1 (ko) * 2011-03-08 2014-02-05 이홍식 자주색 산삼배양근의 제조방법
US9493429B2 (en) * 2013-03-15 2016-11-15 Genentech, Inc. Substituted benzoxazoles and methods of use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521183A (en) * 1994-08-30 1996-05-28 Allergan Use of 5-HT ligands as anti-pruritic agents
EP0834317A1 (en) * 1995-06-14 1998-04-08 Institute of Immunology Co., Ltd. Ameliorant for pruritus cutaneous accompanying renal failure
CN101374833A (zh) * 2006-02-15 2009-02-25 纽瑞姆制药（1991）有限公司 新型吡喃酮-吲哚衍生物及其制备方法
US20130324583A1 (en) * 2006-02-15 2013-12-05 Neurim Pharmaceuticals (1991) Ltd. Methods for treating neurological disease
US20110020436A1 (en) * 2006-09-22 2011-01-27 Guilford F Timothy Topical application of melatonin directly or in liposomes for the amelioration of itching and histamine and non-histamine related inflammatory skin changes
CN105492430A (zh) * 2013-03-15 2016-04-13 基因泰克公司 取代的苯并噁唑及其使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JUN-HO LEE等: "A monoclonal antibody that targets a NaV1.7 channel voltage sensor for pain and itch relief", 《CELL》 *
SHAO-WEN TIAN等: "Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models", 《ACTA PHARMACOLOGICA SINICA》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115279731A (zh) * 2020-03-11 2022-11-01 诺西恩医疗公司 带电的离子通道阻滞剂及其使用方法

Also Published As

Publication number Publication date
KR20190040298A (ko) 2019-04-17
US20190175554A1 (en) 2019-06-13
SG11201901449XA (en) 2019-03-28
AU2017315265A1 (en) 2019-02-28
AU2017315265C1 (en) 2021-06-10
AU2017315265B2 (en) 2021-03-11
EP3503884A1 (en) 2019-07-03
EP3503884B1 (en) 2021-07-21
WO2018037295A1 (en) 2018-03-01
TW201808269A (zh) 2018-03-16
MX381311B (es) 2025-03-12
JP6910424B2 (ja) 2021-07-28
JP2019524797A (ja) 2019-09-05
MX2019002149A (es) 2019-09-18
CA3033534A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
JP7490018B2 (ja) 社会性障害および物質使用障害を治療するための治療用化合物および組成物
JP6991993B2 (ja) 痛覚過敏を治療する方法
US20170266192A1 (en) Methods for improving diaphragm function
CN109843286A (zh) 治疗瘙痒和/或搔痒的方法
US9789117B2 (en) Use of sigma ligands in diabetes type-2 associated pain
EP3606525B1 (en) Compositions for treating aging-associated impairments using ccr3-inhibitors
ES2750662T3 (es) Orvepitant para el tratamiento del prurito crónico
EP3271015B1 (en) Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
PT1410800E (pt) Utilização de 1- ( 4-(5-cianoindol-3-il ) butil )-4-(2-carbamoilbenzofuran-5-il )-piperazina e seus sais fisiologicamente aceitáveis
US20140221385A1 (en) Combinations of serotonin receptor agonists for treatment of movement disorders
JP2014514259A (ja) 疼痛および他の障害の処置のための化合物および方法
US20210401838A1 (en) Identification of agents displaying functional activation of dopamine d2 and d4 receptors
EP3672957A1 (en) Pyrimidine derivatives as tropomyosin receptor kinase a (trka) inhibitors
Dantas et al. Pharmacologic intervention in behavioral therapy
US10568852B2 (en) Combination compositions and their use in methods for treating obesity and obesity-related disorders
EP3833354B1 (en) Tissue transglutaminase modulators for medicinal use
HK40009658A (en) Method for treating pruritus and/or itch
EA042675B1 (ru) Лиганд рецептора гамк-а
HK1242243A1 (en) Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
HK1242243B (en) Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40009658

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190604